NASDAQ:ACOG - Nasdaq - CA02074J5017 - Common Stock - Currency: USD
4.92
+0.36 (+7.89%)
The current stock price of ACOG is 4.92 USD. In the past month the price decreased by -10.22%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.5 | 313.20B | ||
AMGN | AMGEN INC | 14.02 | 149.41B | ||
GILD | GILEAD SCIENCES INC | 23.08 | 132.62B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1698 | 126.59B | ||
REGN | REGENERON PHARMACEUTICALS | 12.88 | 64.26B | ||
ARGX | ARGENX SE - ADR | 319.7 | 36.31B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.48B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.60B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.85B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 24.51B | ||
NTRA | NATERA INC | N/A | 20.08B | ||
BIIB | BIOGEN INC | 7.17 | 17.30B |
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Columbia and currently employs 4 full-time employees. The firm is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. The company is in preclinical development for the treatment of ALS.
ALPHA COGNITION INC
c/o 1200 - 750 West Pender Street
Vancouver BRITISH COLUMBIA CA
Employees: 4
Company Website: https://www.alphacognition.com/
Investor Relations: https://www.alphacognition.com/investors/presentations/
Phone: 16045649244
The current stock price of ACOG is 4.92 USD. The price increased by 7.89% in the last trading session.
The exchange symbol of ALPHA COGNITION INC is ACOG and it is listed on the Nasdaq exchange.
ACOG stock is listed on the Nasdaq exchange.
ALPHA COGNITION INC (ACOG) has a market capitalization of 78.82M USD. This makes ACOG a Micro Cap stock.
ALPHA COGNITION INC (ACOG) currently has 4 employees.
ALPHA COGNITION INC (ACOG) has a support level at 4.91 and a resistance level at 4.93. Check the full technical report for a detailed analysis of ACOG support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ACOG does not pay a dividend.
ALPHA COGNITION INC (ACOG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.01).
ChartMill assigns a technical rating of 1 / 10 to ACOG.
ChartMill assigns a fundamental rating of 3 / 10 to ACOG. No worries on liquidiy or solvency for ACOG as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months ACOG reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS decreased by -40.09% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -28.85% | ||
ROE | -35.3% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to ACOG. The Buy consensus is the average rating of analysts ratings from 7 analysts.